Chesson Labs’ Liquid Bandage Product Receives FDA 510(k) Market Clearance

Chesson Labs has received 510(k) market clearance from the FDA for NUVADERM, the company’s liquid bandage product.

The FDA has cleared claims on the product to cover intact skin and minor cuts, scrapes, burns or irritations of the skin, to help keep them clean and dry and help protect them from infection. The fast application, drying and coverage characteristics make NUVADERM well suited to meet the needs of individuals treating minor wounds. The product also has antimicrobial properties, said the company.

The company anticipates submission of additional filings to the FDA as it continues to expand its product portfolio.

Scott Neuville, president and CEO of Chesson Labs, said: NUVADERM’s clearance is a major milestone for Chesson Labs, but more importantly it is a product developed to improve wound care for individuals treating themselves as well as medical personnel who need a rapid response product to treat minor wounds.